National | July 24, 2026:
Synopsis
- Acquisition: Akums’ wholly-owned subsidiary Pure and Cure Healthcare Pvt. Ltd. to acquire Oriflame India’s manufacturing business.
- Facilities: Includes Roorkee (Uttarakhand) and Noida (Uttar Pradesh) plants, plus a leased warehouse in Noida.
- Consideration: INR 56 crore, purely cash-based.
- Capabilities: Skincare, hair care, wellness, and color cosmetics manufacturing.
- Market Impact: Positions Akums to capture a larger share of India’s USD 20 billion cosmetics market, projected to nearly double in the next decade.
- Completion: Expected by 31st August 2026, subject to closing conditions.
Akums Drugs and Pharmaceuticals Limited (“Akums”), India’s largest Contract Development and Manufacturing Organisation (CDMO), has received Board approval to acquire the manufacturing business of Oriflame India Pvt. Ltd. through its subsidiary Pure and Cure Healthcare Pvt. Ltd.
The acquisition covers two manufacturing facilities in Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse in Noida, for a cash consideration of INR 56 crore.
Manufacturing Capabilities
The acquired facilities bring diverse capabilities across:
- Skincare: Creams, lotions, scrubs, face wash, serums.
- Hair Care: Shampoos, conditioners.
- Color Cosmetics: Lipsticks, foundations, primers, mascara, eyeliners.
- Wellness Products: Various formulations supporting holistic care.
Both plants are equipped with European-make machines for processing, filling, and labelling, supporting small to large batch sizes. They are also Halal certified, enabling global exports.
Strategic Impact for Akums
- Expands footprint in skincare, cosmetics, and wellness manufacturing.
- Marks entry into color cosmetics, a high-growth segment.
- Strengthens Akums’ position in the cosmetics CDMO space.
- Aligns with India’s booming cosmetics and personal care industry, driven by premium demand, e-commerce, omnichannel retail, and social media influence.
Mr. Sanjeev Jain, Managing Director, Akums Drugs and Pharmaceuticals Ltd.: “This acquisition is a significant step in Akums’ strategy to diversify beyond pharmaceuticals into high-growth adjacent categories. Cosmetics, and color cosmetics in particular, represent one of the fastest-growing consumption stories in India today. Acquiring these two well-established manufacturing facilities gives us immediate, high-quality capacity and capability, and strengthens our ability to serve both Indian and global brands.”
Mr. Sandeep Jain, Managing Director, Akums Drugs and Pharmaceuticals Ltd.: “Manufacturing facilities at Roorkee and Noida bring proven expertise and infrastructure that align closely with our quality and scale ambitions. This is a natural extension of our CDMO capabilities into cosmetics, and we see meaningful synergies with our existing operations. Our focus remains on building world-class manufacturing capacity that can cater to the growing demand for skincare and color cosmetics, both domestically and for export markets.”
Mrs. Anna Malmhake, CEO & President, Oriflame: “This agreement represents an important strategic step for Oriflame in India. By partnering with Akums, a highly respected manufacturing company with strong capabilities and a proven track record, we are securing a long-term manufacturing partnership that will continue to support the high-quality products our Beauty Entrepreneurs and customers expect. India remains an important growth market for Oriflame, and we look forward to working closely with Akums while continuing to grow our social selling business across the country.”
Transaction Scope
- Limited to manufacturing business of Oriflame India.
- Marketing, sales, and trademark rights remain with Oriflame India Pvt. Ltd.
- Ensures continuity of Oriflame products for Beauty Entrepreneurs and customers.
